Cormorant Private Healthcare Fund III LP
CIK 1817320 · last filed 2025-06-13
Cormorant Private Healthcare Fund III LP is a corporate insider who has filed 6 SEC Form 4 insider transactions across 5 companies since 2021. The most recent filing, for BMEA, was dated Jun 13, 2025. Across all open-market trades the lifetime net is +$410.8M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $48.9M across reported positions. The firm reports its address in Boston, MA. 51 SEC filings were submitted jointly with Bihua Chen.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
AMAM price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
52ND FLOOR
BOSTON, MA 02116
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BMEA | 10%+ Owner | 3,570,872 | $0.64 | $2.27M | $0 | 1 | 2025-06-13 |
| Ambrx Biopharma Inc. (AMAM) Delisted | 10%+ Owner | 65,474,542 | $28.00 | $1.83B | $276.65M | 2 | 2023-04-20 |
| Verve Therapeutics, Inc. (VERV) Delisted | 984,224 | $11.13 | $10.95M | $20.90M | 1 | 2021-06-23 | |
| RAIN | 2,776,657 | $0.53 | $1.47M | $38.25M | 1 | 2021-04-29 | |
| DSGN | 4,364,844 | $10.34 | $45.13M | $75.00M | 1 | 2021-04-01 |
Recent Filings
6 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-06-13 | BMEA | Grant (A) | — | $0 | EDGAR |
| 2023-04-20 | Ambrx Biopharma Inc. (AMAM) Delisted | Buy (P) | +20,860,756 | $235.80M | EDGAR |
| 2023-03-16 | Ambrx Biopharma Inc. (AMAM) Delisted | Buy (P) | +4,000,000 | $40.85M | EDGAR |
| 2021-06-23 | Verve Therapeutics, Inc. (VERV) Delisted | Mixed | +3,936,896 | $20.90M | EDGAR |
| 2021-04-29 | RAIN | Mixed | +13,883,285 | $38.25M | EDGAR |
| 2021-04-01 | DSGN | Mixed | +25,574,220 | $75.00M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.